Helix BioPharma has started patient enrolment in the second dosing cohort of its US-based Phase I trial (LDOS001) to evaluate its first immunoconjugate-based drug candidate, L-DOS47.

L-DOS47 is being tested in combination with pemetrexed / carboplatin as a treatment for certain patients with non-small cell lung cancer (NSCLC).

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

US-based Helix is a biopharmaceutical firm that develops new drug candidates for the prevention and treatment of cancer.

The Safety Review Committee (SRC) recommended that the company start enroling a new patients, after reviewing safety data from the trial’s first dosing cohort.

Patients enroled in the second cohort will receive the next L-DOS47 dose level, which is 0.78 micrograms of L-DOS47 per kg of patient body weight.

See Also:

L-DOS47 is being developed based on the company’s new DOS47 platform technology, which is designed to modify the microenvironmental conditions of, and eventually eliminate, cancer cells.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The Phase I LDOS001 trial is being carried out in the US at three centres: The University of Texas, M.D. Anderson Cancer Centre, Penn State Milton S. Hershey Medical Center; and University Hospitals Case Medical Center.

The trial’s primary objective is to determine the safety and tolerability of L-DOS47 in combination treatment with pemetrexed / carboplatin.

LDOS002 is an open-label Phase I / II trial being conducted in Poland to evaluate the safety, tolerability and preliminary efficacy of ascending doses of L-DOS47.

The treatment is initially being tested as a monotherapy, in patients with inoperable, locally advanced, recurrent or metastatic, non-squamous, stage IIIb / IV NSCLC.